中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

61 records (took 0.042 seconds)

    COMPOUNDS HAVING THE ANTIGENICITY OF hCG
    44.
    发明申请
    COMPOUNDS HAVING THE ANTIGENICITY OF hCG 审中-公开
    化合物具有hCG的抗生素

    公开(公告)号：WO1995001993A1

    公开(公告)日：1995-01-19

    申请号：PCT/US1994007605

    申请日：1994-07-06

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

    Inventor： UNIVERSITY OF UTAH RESEARCH FOUNDATION ,  HERRON, James, N.

    IPC: C07K14/59

    CPC classification number: C07K14/59 ,  Y10S436/814 ,  Y10S436/818

    Abstract: Disclosed are compounds having antigenic binding affinity with antibodies directed against human chorionic gonadotropin. The compounds typically include or consist of an oligopeptide with the sequence: AA1' AA2' AA3' AA4' AA5' AA6', wherein AA1' is Gly, Asn, Ser, Phe, Arg, Leu, or Lys; AA2' is Pro, Trp, Ala, Val, or Glu; AA3' is Arg, Gln, Ile, Met, Val, Thr, Ser, Gly, or Phe; AA4' is Tyr, Glu, Leu, Phe, Pro, or Thr; AA5' is Asp, Asn, Leu, Met, Val, Tyr, Ser, Ile, Ala, Gly, or Phe; and AA6' is Phe, Trp, Ala, Thr, Arg, Asp, or Val.

    Abstract translation: 公开了与针对人绒毛膜促性腺激素的抗体具有抗原结合亲和力的化合物。 化合物通常包含或由具有以下序列的氨基酸组成：AA1'AA2'AA3'AA4'AA5'AA6'，其中AA1'为Gly，Asn，Ser，Phe，Arg，Leu或Lys; AA2'是Pro，Trp，Ala，Val或Glu; AA3'是Arg，Gln，Ile，Met，Val，Thr，Ser，Gly或Phe; AA4'是Tyr，Glu，Leu，Phe，Pro或Thr; AA5'是Asp，Asn，Leu，Met，Val，Tyr，Ser，Ile，Ala，Gly或Phe; 和AA6'是Phe，Trp，Ala，Thr，Arg，Asp或Val。

    METHODS FOR PREVENTING PROGRESSIVE TISSUE NECROSIS, REPERFUSION INJURY, BACTERIAL TRANSLOCATION AND ADULT RESPIRATORY DISTRESS SYNDROME
    45.
    发明申请
    METHODS FOR PREVENTING PROGRESSIVE TISSUE NECROSIS, REPERFUSION INJURY, BACTERIAL TRANSLOCATION AND ADULT RESPIRATORY DISTRESS SYNDROME 审中-公开
    预防进展性组​​织损伤，再灌注损伤，细菌转移和成熟呼吸综合征的方法

    公开(公告)号：WO1994020111A1

    公开(公告)日：1994-09-15

    申请号：PCT/US1994002558

    申请日：1994-03-08

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION ,  DAYNES, Raymond, A. ,  ARANEO, Barbara, A.

    Inventor： UNIVERSITY OF UTAH RESEARCH FOUNDATION

    IPC: A61K31/56

    CPC classification number: A61K31/569 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575 ,  A61K31/58

    Abstract: The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA or DHEA derivatives to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation of adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA or DHEA derivatives to a patient. Suitable derivatives of DHEA include, among others, 16 alpha -bromo-DHEA, androstenediol and derivatives which have side chains at the 4' and/or 7' positions, which do not destroy the native activity of DHEA but which are capable of inhibiting sulfotransferase to prevent the conversion of DHEA to DHEA-S.

    Abstract translation: 本发明涉及用于预防或减少损伤后缺血的方法，例如缺血后的再灌注损伤，与缺血发作相关的细胞损伤，例如梗死或创伤性损伤，并且因此预防或减少随后的组织相关的进行性坏死 有这样的缺血。 这种作用是通过在受伤后尽快给予患者DHEA或DHEA衍生物来实现的。 本发明还涉及用于预防或减少患者中成人呼吸窘迫综合征的细菌易位的方法。 类似地，通过向患者施用DHEA或DHEA衍生物来预防或减少细菌易位和成人呼吸窘迫综合征。 DHEA的合适衍生物包括16个α-溴-DHEA，雄烯二醇和在4'和/或7'位具有侧链的衍生物，其不破坏DHEA的天然活性，但能够抑制磺基转移酶 以防止DHEA转化为DHEA-S。

    TRANSMUCOSAL DOSAGE FORM
    47.
    发明申请
    TRANSMUCOSAL DOSAGE FORM 审中-公开
    转运剂量形式

    公开(公告)号：WO1991003236A1

    公开(公告)日：1991-03-21

    申请号：PCT/US1990004369

    申请日：1990-08-03

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

    Inventor： UNIVERSITY OF UTAH RESEARCH FOUNDATION ,  STANLEY, Theodore, H. ,  HAGUE, Brian

    IPC: A61K09/68

    CPC classification number: A23G3/368 ,  A23G3/54 ,  A23G3/563 ,  A61J3/00 ,  A61J7/00 ,  A61J7/003 ,  A61K9/0056 ,  A61K31/465

    Abstract: Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates to such compositions and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufacturing techniques that enable therapeutic agents (30) to be incorporated into nondissolvable drug containment matrixes (34) which are capable of releasing the drug within a patient's mouth. An appliance or holder (36) is preferably attached to the drug containment matrix (34). Employing the present invention the drug (30) may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the negative aspects of both of these methods. The nondissolvable drug containment matrix (34) may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The matrix composition (34) may also include pH buffering agents to modify the salival pH thereby increasing the absorption of the drug (30) through the mucosal tissues.

    Abstract translation: 用于生产能够通过口，咽和食道的粘膜组织吸收的药物组合物的组合物和制造方法。 本发明涉及这样的组合物和方法，其可用于以剂量 - 效应方式施用亲脂性和非嗜好性药物，使得施用足够的药物以精确地产生所需效果。 本发明还涉及使治疗剂（30）能够并入不可溶解的药物容纳基质（34）中的制造技术，其能够在患者口腔内释放药物。 器具或保持器（36）优选地附接到药物容纳基质（34）。 使用本发明，药物（30）可以几乎与通过注射一样快地引入患者的血液中，并且比使用口服给药途径快得多，同时避免了这两种方法的不利方面。 不可溶解的药物抑制基质（34）可以包括渗透促进剂以增加口腔粘膜组织的药物吸收。 基质组合物（34）还可以包括pH缓冲剂，以改变游离pH，从而增加药物（30）通过粘膜组织的吸收。

    THE BRCA1 AND 1A1.3B PROMOTERS ARE PARALLEL ELEMENTS OF A GENOMIC DUPLICATION AT 17Q21
    48.
    发明申请
    THE BRCA1 AND 1A1.3B PROMOTERS ARE PARALLEL ELEMENTS OF A GENOMIC DUPLICATION AT 17Q21 审中-公开
    BRCA1和1A1.3B促销商是17Q21的基因重复的平行元素

    公开(公告)号：WO1998023779A1

    公开(公告)日：1998-06-04

    申请号：PCT/US1997021358

    申请日：1997-11-25

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION ,  BARKER, David, F. ,  LIU, Xudong

    Inventor： UNIVERSITY OF UTAH RESEARCH FOUNDATION

    IPC: C12Q01/68

    CPC classification number: C07K14/4702 ,  C12Q1/6886 ,  C12Q2600/172

    Abstract: The results of experiments aimed at detecting polymorphisms and mutations in the BRCA1 promoter region as well as comparisons of two published DNA sequences indicated that two similar but distinct copies of this region exist in the human genome. PCR primers specific for amplification of each of the two promoter regions were isolated from rearrangement-resistant libraries. Sequence analysis of the clones and specific PCR products reveals two similar genomic rearrangements of head-to-head genes. The BRCA1 gene is closely apposed to a gene structure that is similar but not identical to 1A1.3B and the 1A1.3B gene is apposed to a gene structure that has strong similarity to BRCA1 but also has significant differences. The features of the BRCA1 and 1A1.3B promoter region are shown in the Figure. STS analysis of YAC and P1 clones located in the vicinity of BRCA1 indicates that these similar promoter regions are elements of a direct duplication. New hypotheses for genetic mechanisms that may be involved in breast and ovarian cancer etiology are raised by the identification of this duplicated genetic structure on chromosome 17q. Also presented are polymorphisms in the duplicated genes which polymorphisms are useful in tracking chromosomal rearrangement of these genes.

    Abstract translation: 旨在检测BRCA1启动子区域的多态性和突变的实验结果以及两个公开的DNA序列的比较表明，该区域的两个相似但不同的拷贝存在于人类基因组中。 从重排抗体文库中分离出两个启动子区域中的每一个的扩增特异的PCR引物。 克隆和特异性PCR产物的序列分析揭示了头对头基因的两个相似的基因重排。 BRCA1基因与1A1.3B相似但不相同的基因结构密切相关，1A1.3B基因与BRCA1具有强相似性的基因结构具有显着性差异。 BRCA1和1A1.3B启动子区域的特征如图所示。 位于BRCA1附近的YAC和P1克隆的STS分析表明这些类似的启动子区是直接重复的元件。 通过在染色体17q上鉴定这种重复的遗传结构，提出了可能参与乳腺癌和卵巢癌病因的遗传机制的新假设。 还提出了重复基因中的多态性，其多态性可用于跟踪这些基因的染色体重排。

    DIAGNOSIS OF WILLIAMS SYNDROME AND WILLIAMS SYNDROME COGNITIVE PROFILE BY ANALYSIS OF THE PRESENCE OR ABSENCE OF A LIM-KINASE GENE
    49.
    发明申请
    DIAGNOSIS OF WILLIAMS SYNDROME AND WILLIAMS SYNDROME COGNITIVE PROFILE BY ANALYSIS OF THE PRESENCE OR ABSENCE OF A LIM-KINASE GENE 审中-公开
    通过分析LIM-KINASE基因的存在或不存在，诊断威尔斯综合征和威尔斯综合征的认知特征

    公开(公告)号：WO1998001740A2

    公开(公告)日：1998-01-15

    申请号：PCT/US1997011687

    申请日：1997-07-07

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

    Inventor： UNIVERSITY OF UTAH RESEARCH FOUNDATION ,  KEATING, Mark, T. ,  MORRIS, Colleen, A.

    IPC: G01N00/00

    CPC classification number: A61K31/00 ,  A61B17/22 ,  C07K14/78 ,  C12Q1/6827 ,  C12Q1/6841 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158

    Abstract: Williams syndrome (WS) is a developmental disorder that includes poor visuospatial constructive cognition. This syndrome has been studied to identify genes important for human cognitive development. Two families are described which have a partial WS phenotype; affected members have the specific WS cognitive profile and vascular disease, but lack other WS features. Submicroscopic chromosome 7q11.23 deletions cosegregate with this phenotype in both families. DNA sequence analyses of the region affected by the smallest (63.6 kb) deletion revealed two genes, elastin (ELN) and LIM-kinase 1 (LIMK1). The latter encodes a novel protein kinase with LIM domains and is strongly expressed in the brain. Because ELN mutations cause vascular disease but not cognitive abnormalities, these data implicate LIMK1 hemizygosity in impaired visuospatial constructive cognition.

    Abstract translation: 威廉姆斯综合征（WS）是一种发育障碍，包括差的视觉空间建构认知。 已经研究了该综合征，以鉴定对人类认知发育至关重要的基因。 描述了具有部分WS表型的两个家族; 受影响的成员具有特定的WS认知特征和血管疾病，但缺乏其他WS特征。 亚型显示染色体7q11.23缺失与这两种家族中的这种表型相似。 受最小（63.6kb）缺失影响的区域的DNA序列分析显示两个基因，弹性蛋白（ELN）和LIM-激酶1（LIMK1）。 后者编码具有LIM结构域的新型蛋白激酶，并在脑中强烈表达。 因为ELN突变导致血管疾病而不是认知异常，所以这些数据暗示了LIMK1半透明度受损的视空间建设性认知。

Patent Agency Ranking